Indaptus Therapeutics, Inc. Files Form 8-K/A Amendment: Director Name Change and Board Appointment

Key Highlights

• Indaptus Therapeutics, Inc. (NASDAQ: INDP) has filed Amendment No. 1 to its Form 8-K/A, dated April 24, 2026.
• The amendment was made to update the legal name of a recently appointed director, which may have implications for corporate governance and investor transparency.
• The company announced the appointment of a prominent new board member, Tim Ruan, bringing significant experience in finance and biotechnology.
• No other material changes to previously reported disclosures were made.

Details of the Amendment

Indaptus Therapeutics, Inc. filed an amendment to its previously submitted Form 8-K (dated April 23, 2026) to reflect a change in the legal name of a director.
The director previously identified as Yí Zhang (Johnny) has informed the company that his legal name is now Johnny Fox Arrowsmith.
Notably, Dr. Arrowsmith continues to use “Yi Zhang” as his professional name. The company has updated its records and disclosures accordingly.

This update was made solely for the purpose of legal and regulatory accuracy and does not alter any other information in the original filing.

Board Appointment: Tim Ruan

Tim Ruan, age 40, has been appointed as an independent director of Indaptus Therapeutics, Inc. Mr. Ruan is a seasoned financial executive with deep expertise in capital markets, investment banking, and the biotechnology sector.

• Currently serves as the Chief Financial Officer of Ocumension Therapeutics, overseeing financial management, risk, mergers and acquisitions, and investor relations.
• Previously held senior leadership roles at major global financial institutions, including Executive Director at Goldman Sachs (Asia) LLC and Vice President at Morgan Stanley Asia Limited.
• Has led numerous high-profile IPOs and cross-border transactions for leading healthcare and technology companies.
• Educational background includes a Master of Science in Biotechnology from Hong Kong University of Science and Technology, and Bachelor degrees in Commerce (Finance) and Law from the University of New South Wales.

Implications for Shareholders

Potential Price Sensitivity:

• The appointment of Tim Ruan may be viewed positively by investors due to his strong track record in finance and biotech, as well as his experience with public offerings and cross-border transactions. This could enhance the company’s strategic direction and access to capital markets.
• The legal name change and clarification for Dr. Arrowsmith are procedural and do not impact the company’s operations, financials, or governance structure; however, they reflect a commitment to transparency and regulatory compliance.
• No material relationships or related party transactions involving the new directors were disclosed, nor any arrangements pursuant to which they were appointed, indicating a straightforward addition to the board.
• No other amendments or updates to previously reported information were made, and the original report continues to speak as of the date it was filed.

Regulatory and Stock Information

• Security Registered: Common Stock, \$0.01 par value
• Trading Symbol: INDP
• Exchange: Nasdaq Capital Market
• Emerging Growth Company Status: Indaptus is not an emerging growth company as defined by SEC rules.

Conclusion

Investors should note the addition of a highly experienced director to the board, which may signal strategic moves in capital markets or corporate development. The legal name update for another director is administrative but underscores the company’s attention to compliance. No other material changes were announced.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. All information is based on publicly available filings and should be independently verified. Investors should consult their financial advisors before making any investment decisions. Indaptus Therapeutics, Inc. and its securities may be subject to risks not discussed in this article.

View Indaptus Therapeutics, Inc. Historical chart here